may, however, coexist with infection of the vagina and cervix uteri, with bacteria such as Chlamydia trachomatis, protozoa such as Trichomonas vaginalis, or fungi such as Candida albicans, which may cause an inflammatory reaction.
Nitroimidazoles have been shown to be the drugs of choice in treating women with bacterial vaginosis.4
Some workers have suggested that the recurrence of symptoms may be caused by reinfection by their male consorts and that treating their sexual partners may decrease the recurrence rate.4`Until recently, no controlled studies had been undertaken to confirm or reject this theory.
The purpose of the present study was to investigate the recurrence rate of bacterial vaginosis in women in relation to concomitant treatment of their consorts.
The study was designed as a long term international multicentre double blind trial. The dose of metronidazole was chosen according to the recommendations of a Norwegian multicentre study, which showed a cure rate of 94% after four weeks.6 263 Moi, Erkkola, Jerve, Nelleman, Bymose, Aslaksen, Tornqvist Patients and methods
PATIENTS
The study comprised non-pregnant sexually active women aged 17-56 (median 32) years with a diagnosis of bacterial vaginosis who attended one of the four clinics participating in the study. To be included, each patient had to have at least three of the four following symptoms or signs: (a) thin, greyish, sticky vaginal discharge; (b) pH of the vaginal discharge 4.5 or more; (c) a fishy amine odour after mixing 10% potassium hydroxide with the discharge on a glass slide; and (a) clue cells in a wet smear of the vaginal discharge. At least two symptoms or signs had to have resolved for bacterial vaginosis to be considered cured, but in general all symptoms and signs had resolved in cured patients.
Each patient included had one male consort with whom she had sexual intercourse, without using a condom, at least once a week during the study period. Few of the men were circumcised, as circumcision is rare in the Nordic countries. The men were not examined, except those attending one centre (Sweden).
Criteria for exclusion were pregnancy or lactation, hematological or neurological disease, a history of allergy to metronidazole, or antibiotic treatment in the preceding week.
We enrolied into the study 241 women who fulfilled the criteria given above, and their male consorts (table  1) . They consisted of 100 women attending the department of obstetrics and gynaecology of University Central Hospital, Turku, Finland, 70 attending the department of gynaecology of Ulleval University Hospital, Oslo, Norway, 35 attending a private clinic for gynaecology in Odense, Denmark, and 36 attending the outpatient clinics for gynaecology and for sexually transmitted diseases at Orebro Medical Center Hospital, Orebro, Sweden. The trial was approved by the local ethical committees, and informed consent was given by the patients and their consorts.
DESIGN OF THE STUDY
All the 241 women with bacterial vaginosis were treated with an initial dose of 2 g metronidazole that Patients whose signs of bacterial vaginosis had recurred at follow up visits were asked about symptoms. Those who had symptoms were treated with metronidazole and withdrawn from the study, as were women who had received other antibiotics during the study period.
MICROBIOLOGICAL EXAMINATION
Material for cultures for C trachomatis and for Neisseria gonorrhoeae was taken at the first and last visits, and patients with gonorrhoea or chlamydial infection were withdrawn from the study because they received additional antibiotic treatment. The routines for each of the clinics were followed. At one of the participating centres (Orebro, Sweden), vaginal specimens from 31 women and specimens from the -urethra and the preputial cavity from 22 male consorts were collected with cotton tipped swabs and trans-Should male consorts of women with bacterial vaginosis be treated? ported to the laboratory in modified Stuart's medium.'
The samples were inoculated on to selective differential bilayer HB agar (human blood bilayer agar containing 15 mg colistin and 10 mg nalidixic acid/ml) for semiquantitative cultures for Gardnerella vaginalis. 8 The strains isolated were characterised by oxidase, catalase, ,B glucosidase, hippurate, and a glucosidase tests.8 Growth on the agar plates was graded as moderate, abundant, or none. At the Orebro clinic, specimens were taken from the women and their male consorts for anaerobic culture ofMobiluncus spp using supplemented brain heart infusion agar.' Strains isolated were characterised by morphology (Gram stain), sensisitivity to metronidazole, and biochemical (hippurate, oxidase, and catalase) tests.'`Material was also taken from each man for culture for C trachomatis and for Ngonorrhoeae.
STATISTICS
Differences between the treatment groups were tested statistically using the x2 test with Yates's correction and a two sided significance level of 5%. Statistical tests were performed on numbers including patients who had dropped out or had been withdrawn (according to the principle of intention to treat) and without including such patients. In general, the differences between these numbers were small. Table 2 summarises the relative occurrence of each of the individual criteria for diagnosing bacterial vaginosis in the 241 women enrolled in the study. The findings in the two groups were similar. Clue cells showed the best correlation with a diagnosis of bacterial vaginosis and were documented in 98% (235/240) of the patients, followed by a positive amine test in 97% (229/237) and a pH of 4.5 or more in 94% (225/240). Increased vaginal discharge was noted by 89% (212/239) of the women and observed by the doctor in 87% (209/240). G vaginalis was cultured in 88% (122/138) specimens from women. C trachomatis was cultured in six (5%) of 121 patients who were therefore withdrawn from the study after the first follow up visit. None of the patients yielded N gonorrhoeae on culture. Trichomoniasis was found by microscopy in one patient, but not in any of the 65 for whom culture for T vaginalis was carried out. The figure and tables 3-5 summarise the results at weeks 1, 4, and 12 after treatment. In the group of women whose male consorts were treated' with metronidazole, 97% (115/119) were cured after one week, but relapse had occurred in 17% (19/112) after four weeks and in 21% (20/95) after 12 weeks. In the group of women whose male partners had received placebo 98% (111/113) were cured at week 1 but 13% (49/106) and 16% (15/95) respectively, had had relapses at weeks 4 and 12. The differences between the two groups of women were thus not significant. Four weeks after treatment, two patients were withdrawn from the study because of chlamydial infection and one had dropped out. In the remaining 28 patients recurrence was diagnosed in four whose consorts had received metronidazole (three of whom received additional treatment and were withdrawn) and in one of the others (who was withdrawn from the study because of receiving additional treatment). Vaginal culture from the remaining 13 women whose consorts had received metronidazole showed abundant growth of G vaginalis in eight and no growth in five samples; of the 15 women whose consorts had received placebo, seven had abundant and eight no growth. M curtisii was isolated from one woman in whom recurrence was diagnosed.
Results
Twelve weeks after treatment, four women were withdrawn from the survey because they had been treated for relapse, and two had dropped out. Of the remaining nine women whose consorts had received metronidazole, four had relapsed and had abundant growth of G vaginalis in vaginal fluid (one negative in the Hippurate test). Ofthe five women without signs of bacterial vaginosis, two had abundant growth, one had a moderate growth, and one had no growth of G vaginalis, and culture failed in one. Of the remaining 13 women whose consorts had received placebo, two had relapses and abundant growths of G vaginalis in vaginal fluid, as did six other women without signs of bacterial vaginosis. Five women who were free from signs of bacterial vaginosis had no growth of G vaginalis. Four patients whose consorts had received metronidazole and 11 of the others were still cured according to the composite clinical criteria. A long curved rod was isolated, but not typed because ofweak growth, from one woman whose partner had yielded M curtisii on day 1.
MALE CONSORTS
Of the 22 male consorts examined at Orebro, Sweden, seven (32%) yielded G vaginalis from the urethra at the first visit, none had signs of urethritis in stained urethral smears, and two yielded M curtisii from the preputial sack. Of 13 men followed up one week after treatment, three yielded G vaginalis. These three men had all been treated with metronidazole, No significant correlation was seen between finding G vaginalis in a man and the recurrence of bacterial vaginosis in his female consort. Should male consorts ofwomen with bacterial vaginosis be treated? Pseudomycelium was found on microscopy of wet smears from the vaginas of 5-12% of the patients at the follow up visits (see tables [3] [4] [5] . As culture for yeasts was performed in only about half the patients, the culture results are not shown in the tables. At week 4 two (9%) of the 22 women with hyphae in their wet smears had signs of recurrence of bacterial vaginosis, but only one of the two yielded C albicans'on culture.
At week 1 The findings of the present and other studies support the concept that bacterial vaginosis is the expression of a clinical syndrome with multifactorial and multibacterial aetiologies. The present study also shows that treating consorts is of no value in curing patients. Although sexual activity may be important in establishing bacterial vaginosis, sexual transmission of agents sensitive to metronidazole does not seem to be a major cause of recurrences. 
